Group 1 - The core viewpoint of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.3%, reaching 169.00 CNY per share, with a total market capitalization of 10.728 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - Huafu Fund has a significant holding in Haobo Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 32,000 shares, representing 5.87% of the fund's net value [2] - The fund has achieved a year-to-date return of 64.07%, ranking 409 out of 8172 in its category, and a one-year return of 69.47%, ranking 1687 out of 7980 [2] - The fund manager, Liao Qingyang, has been in charge for 3 years and 313 days, with the best fund return during this period being 43.34% [2]

Core Viewpoint - The stock of Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a decline of 5.42% on September 15, closing at 157.01 CNY per share, with a trading volume of 106 million CNY and a turnover rate of 1.05%, resulting in a total market capitalization of 9.967 billion CNY [1] Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. was established on June 8, 2009, and is located at No. 9, Dongyanli Road, Suzhou Industrial Park. The company was listed on January 13, 2021 [1] - The main business involves the research, production, and sales of in vitro diagnostic reagents. The revenue composition is as follows: reagent sales account for 89.46%, other sales for 5.86%, instrument sales for 3.84%, and rental sales for 0.85% [1] Fund Holdings - According to data, one fund under Shenwan Hongyuan holds a significant position in Haobio. The Shenwan Hongyuan Medical Pioneer Stock A (005433) held 56,100 shares in the second quarter, representing 5.74% of the fund's net value, making it the sixth-largest holding [2] - The fund was established on November 16, 2020, with a current scale of 120 million CNY. Year-to-date returns are 5.7%, ranking 3857 out of 4222 in its category; over the past year, returns are 25.13%, ranking 3518 out of 3802; since inception, the fund has incurred a loss of 43.08% [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 60 days, with the total asset scale currently at 133 million CNY. The best fund return during his tenure is -23.18%, while the worst is -24.16% [2]

Group 1 - The core viewpoint of the news is that Haobo Biopharmaceutical Co., Ltd. has seen a significant increase in its stock price, rising 5.46% on September 12, with a total market capitalization of 9.808 billion yuan and a cumulative increase of 12.93% over four consecutive days [1] - Haobo's main business involves the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its revenue, other sales at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] - The company is located in Suzhou Industrial Park and was established on June 8, 2009, with its listing date on January 13, 2021 [1] Group 2 - From the perspective of major fund holdings, one fund under Nuoan Fund has heavily invested in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, representing 5.9% of the fund's net value, making it the third-largest holding [2] - The fund has seen a floating profit of approximately 137,100 yuan today and a total floating profit of 287,300 yuan during the four-day increase [2] - Nuoan Jingxin Mixed Fund was established on December 8, 2015, with a current scale of 39.4081 million yuan and has achieved a year-to-date return of 41.35% [2]

Group 1 - The company plans to purchase liability insurance for its directors, supervisors, and senior management to protect investor interests and reduce operational risks [1][26] - The insurance coverage limit is set at a maximum of RMB 50 million, with an annual premium not exceeding RMB 250,000 [1] - The decision to purchase insurance will be submitted for approval at the upcoming extraordinary general meeting of shareholders scheduled for September 25, 2025 [1][3] Group 2 - The extraordinary general meeting will be held on September 25, 2025, at 10:00 AM in the company's conference room [4] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's online voting system [4][6] - Shareholders must register for the meeting by September 24, 2025, and can delegate their voting rights to a proxy [10][15] Group 3 - The company has recently completed the cancellation of its special account for raised funds, as the related project has concluded [21][22] - The total amount raised from the initial public offering was RMB 555.86 million, with a net amount of RMB 496.47 million after deducting issuance costs [21] - The funds from the special account have been fully utilized, and the remaining interest of RMB 96.84 has been transferred to the company's main account [22]

Core Viewpoint - The company, Haooubo, announced the approval of a proposal to purchase liability insurance for its directors, supervisors, and senior management during the 21st meeting of its third supervisory board [2] Summary by Categories Company Actions - The company held its 21st meeting of the third supervisory board on September 9, where it approved the proposal for purchasing liability insurance for its directors, supervisors, and senior management [2]

Core Points - The company, Haooubo, announced the establishment of a special account for the management of funds raised from its initial public offering (IPO) in compliance with relevant laws and regulations [1] - Recently, the company completed the procedures for the cancellation of the special account for the raised funds [1]

证券代码：688656 证券简称：浩欧博 公告编号：2025-056 江苏浩欧博生物医药股份有限公司 关于注销募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）首次公开发行股票募 集资金按照相关法律法规及规范性文件的规定开设了募集资金专项账户以对募集 资金实施专户管理，严格控制募集资金使用的各个环节。公司于近日办理了相关募 集资金专户的注销手续，现将有关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2020 年 12 月 15 日出具的《关于同意江苏浩 欧博生物医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕3415 号），公司获准向社会公开发行人民币普通股 1,576.4582 万股，每股发行价格为 人民币 35.26 元，募集资金总额为人民币 55,585.92 万元；扣除发行费用后实际募 集资金净额为人民币 49,646.58 万元。上述资金已全部到位，立信会计师事务所（特 殊普通合伙）对公司本次公开发行新股的 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-054 江苏浩欧博生物医药股份有限公司 关于为董事、监事及高级管理人员购买责任保险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日召 开第三届董事会第二十七次会议及第三届监事会第二十一次会议，审议《关于为董事、 监事及高级管理人员购买责任保险的议案》。因公司全体董事、监事为被保险对象， 基于谨慎性原则，全体董事、监事已回避表决，上述议案将直接提交公司 2025 年第 三次临时股东大会进行审议。 为保障广大投资者利益、降低公司运营风险，同时促进公司管理层充分行使权利、 履行职责，根据《上市公司治理准则》等相关规定，公司拟为公司及控股子公司董事、 监事及高级管理人员购买责任保险，具体方案如下： 1、投保人：江苏浩欧博生物医药股份有限公司 2、被保险人：公司及控股子公司全体董事、监事及高级管理人员 3、责任限额：不超过人民币 5,000 万元（具体以保险合同为准） 4、保费金额： ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-055 江苏浩欧博生物医药股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 召开日期时间：2025 年 9 月 25 日 10 点 00 分 召开地点：公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 25 日 至2025 年 9 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年9月25日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-053 江苏浩欧博生物医药股份有限公司 第三届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏浩欧博生物医药股份有限公司（以下简称"公司"）第三届监事会第二 十一次会议于 2025 年 9 月 4 日发出通知，并于 2025 年 9 月 9 日 13 时在公司会议 室召开。本次会议应到监事 3 名，实到监事 3 名，会议由监事会主席焦海云女士 主持。会议的召集、召开及表决程序符合《中华人民共和国公司法》和《公司章 程》的有关规定。 二、监事会会议审议情况 1.《关于为董事、监事及高级管理人员购买责任保险的议案》 为保障广大投资者利益、降低公司运营风险，同时促进公司管理层充分行使 权利、履行职责，根据《上市公司治理准则》等相关规定，公司拟为董事、监事 及高级管理人员购买责任保险。 表决情况：基于谨慎性原则，全体监事回避表决。本议案将提交公司 2025 年第三次临时股东大会进行审议。 具体内容详见公司同日于上 ...